AZD0530, AN INHIBITOR OF SRC KINASES, IN PLATINUM-PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A TRIAL OF THE PMH PHASE II CONSORTIUM

被引：0
|
作者：
Laurie, Scott A. [1 ]
Goss, Glenwood D. [1 ]
Shepherd, Frances A. [2 ]
Reaume, Neil [1 ]
Nicholas, Garth [1 ]
Philip, Lindsay [2 ]
Wang, Lisa [2 ]
Oza, Amit [2 ]
Hirsh, Vera [3 ]
Wright, James
Leighl, Natasha [2 ]
机构：
[1] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON, Canada
[3] Mcgill Univ Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
src kinase inhibitor; non-small cell; Phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1262 / S1262
页数：1
相关论文
共 50 条
  • [31] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
  • [32] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [33] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [34] A phase II trial of denileukin difititox- in previously treated, advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    Shukla, R
    Kleykamp, B
    Jazieh, AR
    Hainsworth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 689S - 689S
  • [35] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)-Final report
    Sovak, M. A.
    Guensch, L.
    Joyce, P.
    Lutzker, S. G.
    Schwartz, S.
    Shih, W. J.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [37] Phase II trial of concurrent erlotinib in locally advanced non-small cell lung cancer (LA-NSCLC)
    Hansen, O.
    Knap, M.
    Khalil, A.
    Nyhus, C.
    Brink, C.
    Hoffmann, L.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S663 - S663
  • [38] A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 653S - 653S
  • [39] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    LUNG CANCER, 2005, 49 : S242 - S242
  • [40] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).
    Lynch, TJ
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Govindan, R
    Janne, PA
    Hanna, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
12345